Ovarian Neoplasms: all 2,757 studies
Page 7 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- AOH1996 for the Treatment of Refractory Solid TumorsRecruitingNCT05227326Phase 1
- Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian CancerRecruitingNCT05211557Phase 1/2
- A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian CancerRecruitingNCT05206890
- Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerRecruitingNCT05200260Phase 2
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingNCT05187208Phase 4
- Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian CancerRecruitingNCT05183984Phase 2
- CADx - Radiomics to Distinguish the Origin of Ovarian TumorsRecruitingNCT05174377
- PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPIRecruitingNCT05172310Phase 1
- Avera Cancer Sequencing and Analytics Protocol (ASAP)RecruitingNCT05142033
- CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and TestingRecruitingNCT05130606Not applicable
- Registry Platform Ovarian and Endometrial CancerRecruitingNCT05129969
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT05128825Phase 2
- Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)RecruitingNCT05123807Phase 2
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
- First-in-human Study of OVM-200 as a Therapeutic Cancer VaccineRecruitingNCT05104515Phase 1
- First in Human Study of TORL-1-23 in Participants With Advanced CancerRecruitingNCT05103683Phase 1
- Microtransplantation for Ovarian CancerRecruitingNCT05095558Phase 1/2
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
- A Beta-only IL-2 ImmunoTherapY StudyRecruitingNCT05086692Phase 1/2
- Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian CancerRecruitingNCT05080556Phase 2
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruitingNCT05071937Phase 2
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruitingNCT05051722
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
- Transcriptional Map of Ovarian Cancer at the Single Cell LevelRecruitingNCT05030805
- 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.RecruitingNCT05025878
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingNCT05009082Phase 3
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
- Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving ChemotherapyRecruitingNCT04997096Not applicable
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRecruitingNCT04981119
- Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2
- Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerRecruitingNCT04921527Phase 3
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingNCT04918186Phase 2
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT04895709Phase 1/2
- Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These CancersRecruitingNCT04891029Not applicable
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationRecruitingNCT04890613Phase 1
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsRecruitingNCT04851119Phase 1/2
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingNCT04847063Phase 1
- PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian CancerRecruitingNCT04815408Phase 2
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian CancerRecruitingNCT04811703Phase 1
- Developing a Test of Uterine Lavage for the Detection of Ovarian CancerRecruitingNCT04794322
- Prehabilitation in Gynaecological Cancer PatientsRecruitingNCT04789694Phase 3
- A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerRecruitingNCT04787289Phase 2
- Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.RecruitingNCT04778839Phase 1
- The Culture of Ovarian Cancer Organoids and Drug ScreeningRecruitingNCT04768270
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)RecruitingNCT04752826Phase 1/2
- Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer PatientsRecruitingNCT04751435Not applicable
- Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian CancerRecruitingNCT04747717Not applicable
- Lymphadenectomy in Early Ovarian CancerRecruitingNCT04710797Not applicable
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingNCT04701645Phase 1
- Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.Enrolling by invitationNCT04699006
- A First-in-Human, JAB-8263 in Adult Patients With Advanced TumorsRecruitingNCT04686682Phase 1/2
- Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)RecruitingNCT04678102Phase 1
- Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer SurgeryRecruitingNCT04665635Not applicable
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsRecruitingNCT04657068Phase 1/2
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2
- Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT04606914Phase 2
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingNCT04590326Phase 1/2
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingNCT04585750Phase 1/2
- Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialRecruitingNCT04575935Phase 3
- Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesAvailableNCT04566393
- Prospective Study of Immune Alterations in Operable Breast and Ovarian CarcinomaRecruitingNCT04562623
- Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBTRecruitingNCT04520139Phase 1/2
- Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)RecruitingNCT04520074Phase 3
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingNCT04518501Phase 1/2
- Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)Not yet recruitingNCT04515602Phase 3
- Transvaginal Ultrasonography as a Screening Method for Ovarian CancerRecruitingNCT04473833Not applicable
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingNCT04469764Phase 2
- Connected Prehabilitation Program During Neo Adjuvant ChemotherapyNot yet recruitingNCT04451369Not applicable
- Factors Affecting the Prognosis of Early Ovarian CancerRecruitingNCT04414683
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingNCT04329494Phase 1
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
- TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of PreventionRecruitingNCT04294927Not applicable
- PROADAPT-ovary/EWOC-2RecruitingNCT04284969Not applicable
- Intensive Intraperitoneal Therapy in Advanced Ovarian CancerRecruitingNCT04282356Phase 2
- DOvEEgene Fleur: New Uterine Sampling ToolRecruitingNCT04258449
- A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerRecruitingNCT04251052Not applicable
- BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAvailableNCT04091295
- Phase III Trial of Stage I Ovarian Cancer After SurgeryRecruitingNCT04063527Phase 3
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingNCT04055649Phase 2
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsRecruitingNCT04038619Phase 1
- Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting HypoxiaRecruitingNCT04001023Not applicable
- Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)RecruitingNCT03983226Phase 2
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
- Deciphering Mechanisms Underlying Cancer ImmunogenicityRecruitingNCT03958240Not applicable
- Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With CancerRecruitingNCT03943316
- APG-2449 in Patients With Advanced Solid TumorsRecruitingNCT03917043Phase 1
- Clinical Pre-screening Protocol for Ovarian CancerRecruitingNCT03877796
- A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With GemcitabineRecruitingNCT03854110Phase 1
- Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by invitationNCT03762733
- Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsRecruitingNCT03755739Phase 2/3
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/2
- Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene MutationRecruitingNCT03667417
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFRecruitingNCT03604315Phase 1